AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8840939
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + bicarbonate
Trial: 8840939
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + saline
Trial: 8840939
Drug: Albuterol +
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol + bicarbonate
Trial: 8840939
Drug: Albuterol +
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol + saline
Trial: 1473671
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no intravenous sedative)
Trial: 25305728
Drug: MACS (magnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACS (magnetic activated cell sorting) with swim-up preparation
Trial: 25305728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (swim-up preparation)
Trial: 19854483
Drug: 5% tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% tramadol (2 mg/kg) plus adrenaline (0.0125/mL)
Trial: 19854483
Drug: 2% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% prilocaine plus adrenaline (0.0125/mL)
Trial: 12359778
Drug: CAIV-T (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAIV-T (first dose)
Trial: 12359778
Drug: CAIV-T (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAIV-T (second dose)
Trial: 10426648
Drug: Indoramin 20
RxNorm normalized name: indoramin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 20 mg orally twice a day
Trial: 1969208
Drug: Ketoconazole shampoo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole shampoo, twice weekly for 4 weeks
Trial: 7286046
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg) evening ingestion
Trial: 7286046
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg) morning ingestion
Trial: 27604762
Drug: Brilliant blue
RxNorm normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brilliant blue G (BBG)
Trial: 21285719
Drug: Medical expulsive
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical expulsive therapy with alpha-blockers
Trial: 18953506
Drug: Adjuvant sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant sodium selenite 0.2 mg kg(‐1) day(‐1) for 7 days in addition to chemotherapy
Trial: 14982568
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of hyperbaric tetracaine with 0.2 mg of epinephrine (SE Group)
Trial: 14982568
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of hyperbaric tetracaine (L Group)
Trial: 14982568
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg of hyperbaric tetracaine (S Group)
Trial: 16758422
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of primary prophylaxis
Trial: 16758422
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of secondary prophylaxis
Trial: 9458381
Drug: 5-HT3-Receptor Antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-HT3-Receptor Antagonist (5-HT3-RA)
Trial: 9458381
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral metoclopramide (20 mg q.i.d.) + i.m. Dexamethasone (M + D)
Trial: 2455099
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA), 100 mg p.o./day plus tamoxifen (TAM), 100 mg p.o./day
Trial: 2455099
Drug: Flutamide (FLU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (FLU), 750 mg p.o./day
Trial: 21275333
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (15-35 minute session with live patient-preferred music and therapeutic social interaction)
Trial: 17560638
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs (corticosteroids)
Trial: 8478475
Drug: Argon laser
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon laser treatment for mature nodular port-wine stains, telangiectasia, small vascular lesions, and superficial pigmented lesions.
Trial: 3928674
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) at 50 micrograms/24 h and higher
Trial: 3928674
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) at 25, 50, 100, and 200 micrograms/24 h
Trial: 29927201
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose proton pump inhibitor (PPI) - intravenous pantoprazole 80 mg bolus then continuously drip 8 mg per hour
Trial: 29927201
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose proton pump inhibitor (PPI) - intravenous pantoprazole 40 mg twice daily
Trial: 29927201
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose proton pump inhibitor (PPI)
Trial: 29927201
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose proton pump inhibitor (PPI)
Trial: 24118885
Drug: AZD7687 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7687 (1, 2.5, 5, 10 and 20 mg/day)
Trial: 24118885
Drug: AZD7687 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7687 (doses >5 mg/day)
Trial: 18331385
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein thresholds (40, 60, 120 mg/l)
Trial: 18331385
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of raised CRP concentration with clinical diagnosis of pneumonia
Trial: 15944791
Drug: Platinum-based combination
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based combination chemotherapy (CTX)
Trial: 15944791
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (no-CTX)
Trial: 15944791
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy (CTX)
Trial: 15944791
Drug: Second-line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line chemotherapy (CTX)
Trial: 12582393
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolevulinate (MAL) 160 mg/g
Trial: 30596964
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin suspension (50 mg/kg/day) for 3 days
Trial: 30596964
Drug: Oral co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days
Trial: 27813031
Drug: IV dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dexketoprofen trometamol (50 mg)
Trial: 27813031
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (1 gr)
Trial: 27813031
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic (Control Group K)
Trial: 22617396
Drug: BOLUS (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOLUS (25 g of whey protein + 5 g of leucine dissolved in artificially sweetened water; 1 × 500 mL)
Trial: 22617396
Drug: PULSE (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PULSE (15 × 33‐mL aliquots of BOLUS drink every 15 min)
Trial: 20033128
Drug: Transurethral microwave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral microwave therapy (TUMT)
Trial: 15690909
Drug: Gepon 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepon 0.04% ointment
Trial: 15690909
Drug: Immunomax 200
RxNorm normalized name: IMMUNOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomax 200 units intramuscularly, administered 3 times every 2nd day
Trial: 15690909
Drug: Routine surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine surgical treatment and drug therapy (control group)
Trial: 12577246
Drug: Intravenous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amifostine (200 mg/m2/d in a short 3‐minute infusion 15 to 30 minutes before each fraction of radiotherapy)
Trial: 12577246
Drug: Subcutaneous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous amifostine (500 mg/d in two, slow 1.25‐mL injections at two different sites 20 to 60 minutes before each radiotherapy fraction)
Trial: 27094489
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment specified)
Trial: 23505124
Drug: Aripiprazole 9.75
RxNorm normalized name: ARIPIPRAZOLE 9.75MG/1.3ML (7.5MG/ML) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 9.75 mg IM injection
Trial: 21682350
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (two NRTIs + DRV/r)
Trial: 15900378
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 40 mg/kg/day in 5% dextrose
Trial: 8688215
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin (100 mg/m2, D1) and fluorouracil (1 g/m2, D2‐4) followed by regional treatment
Trial: 8688215
Drug: Regional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional treatment alone
Trial: 22115397
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy initiation
Trial: 29076171
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (2 sessions weekly for 12 weeks)
Trial: 25017530
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 mcg once daily
Trial: 17400672
Drug: Supplemental O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental O2 therapy
Trial: 15724143
Drug: High-dose levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose levothyroxine (L-T(4)), mean dose 320 microg/day, adjunctive treatment for 7 weeks
Trial: 15724143
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (age-matched healthy women without L-T(4) treatment)
Trial: 9471040
Drug: Casodex 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 100 mg daily
Trial: 9471040
Drug: Casodex 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 200 mg daily
Trial: 9471040
Drug: Casodex (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex (all doses)
Trial: 7613148
Drug: Oral provocation
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral provocation tests (OPTs) with the suspected drug
Trial: 7613148
Drug: Concomitant ARs
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant ARs to other mild analgesics during OPTs
Trial: 7613148
Drug: Oral provocation
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral provocation tests (OPTs)
Trial: 7613148
Drug: Standard battery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard battery of different analgesics in OPTs
Trial: 7613148
Drug: Single preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preparation recommendation (e.g., acetaminophen) without OPT
Trial: 31298405
Drug: 40:1 MI/DCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40:1 MI/DCI ratio, 2 g of inositols twice a day for 3 months
Trial: 28091438
Drug: 0.75 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml/kg of 0.25% bupivacaine
Trial: 28091438
Drug: 0.5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg of 0.25% bupivacaine
Trial: 27443567
Drug: Cinacalcet (CC)
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet (CC) with Sevelamer (SV)
Trial: 27443567
Drug: Cinacalcet (CC)
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet (CC) with Calcium Salts (CS)
Trial: 17624996
Drug: Single-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-blind placebo administration
Trial: 10624256
Drug: Risk assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk assessment and classification of pressure ulcers performed daily by nurses using the Modified Norton Scale (MNS) and a 'Pressure Ulcer Card'.
Trial: 7611822
Drug: Topical IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical IFN gamma-1 beta gel
Trial: 31441893
Drug: BoNTA injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BoNTA injection (5 IU/cm)
Trial: 27683185
Drug: Calcium (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (2000 mg) and Vitamin D (1000 IU) supplementation
Trial: 26123629
Drug: Gabapentin (100-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (100-600 mg/day)
Trial: 26123629
Drug: Clonazepam (0.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.5-2 mg/day)
Trial: 23175556
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate 6 mg/kg/d (once-daily or twice-daily) for 7 days
Trial: 23175556
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate 8 mg/kg/d (once-daily or twice-daily) for 3 days, followed by mefloquine
Trial: 23175556
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (including both doses and schedules)
Trial: 15532847
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus preoperative treatment with recombinant human IL‐2 (9,000,000 IU for three consecutive days)
Trial: 15532847
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus preoperative treatment with recombinant human IL‐2
Trial: 11804379
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for small-cell lung cancer (SCLC)
Trial: 11804379
Drug: Surgery or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery or palliative chemotherapy for non-small-cell lung cancer (NSCLC)
Trial: 11804379
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life measurement tools (EORTC LC-13, FACT-L, LCSS)
Trial: 7894627
Drug: 0.05% levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% levocabastine eye drops and nasal spray plus topical placebos (twice daily)
Trial: 7894627
Drug: 2% sodium
RxNorm normalized name: Dextrose 5% and 0.2% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% sodium cromoglycate eye drops and nasal spray (four times daily)
Trial: 3499074
Drug: Sucralfate suspension
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate suspension (1 g/10 ml every four hours)
Trial: 3499074
Drug: Antacid titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid titration (to maintain a gastric pH of more than 4)
Trial: 21076278
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) 400 mg daily
Trial: 9262126
Drug: Dextromethorphan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (150 mg daily)
Trial: 30938645
Drug: SDF solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDF solution
Trial: 30938645
Drug: SDF solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDF solution followed by potassium iodide (KI) solution
Trial: 15741544
Drug: Mirazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirazid (300 mg/day for three consecutive days)
Trial: 15741544
Drug: Praziquantel (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (single dose of 40 mg/kg)
Trial: 12875093
Drug: Home enteral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home enteral nutrition (HEN) with a mean of 1650 Kcal of enteral solution
Trial: 7762065
Drug: Enisoprost (EP)
RxNorm normalized name: acetaminophen
DrugBank: Enisoprost (DB19319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enisoprost (EP) 100 mg p.o. t.i.d. for 12 weeks
Trial: 28110408
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment with distraction osteogenesis (DO)
Trial: 17596694
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Iscador therapy)
Trial: 10093796
Drug: Intraarticular injections
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injections of sodium hyaluronate (20 mg) plus steroid (20 mg triamcinolone acetonide) and physiotherapy
Trial: 10093796
Drug: Intraarticular injections
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injections of steroid (20 mg triamcinolone acetonide) alone and physiotherapy
Trial: 2945705
Drug: 1% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metronidazole in an emollient cream base
Trial: 2945705
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral tetracycline taken twice daily
Trial: 27016729
Drug: First-generation antipsychotics
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotics (haloperidol and flupentixol)
Trial: 27016729
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (olanzapine, aripiprazole and quetiapine)
Trial: 20473735
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule (600 mg, twice a day) and Valsartan (80 mg once a day)
Trial: 20473735
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule and Valsartan vs Control group
Trial: 20473735
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule and Valsartan vs Valsartan group
Trial: 15470940
Drug: School-based drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based drug abuse prevention program
Trial: 15470940
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drug prevention program)
Trial: 30159739
Drug: Knee brace
RxNorm normalized name: Knee Brace Large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee brace (12 weeks postoperative therapy)
Trial: 30159739
Drug: Wedge insoles
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wedge insoles (12 weeks postoperative therapy)